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Abstract 
Economic evaluation has become an important tool in health and transport economics. To 
evaluate decisions, thresholds and benchmark values are required. These thresholds can 
include valuating lives in monetary form. To ensure an efficient distribution of resources the 
value of human life should be approximately the same between the sectors. In transport 
economics value of statistical life (VSL) is frequently used and in health economics the value 
of a quality-adjusted life-year (QALY) is frequently used to compare costs and benefits. I 
calculate and create a confidence interval (CI) for the transformed VSL in ten countries using 
official data. In order to see if there is coherence between the sectors the transformed VSL is 
compared to the threshold QALY values used in the health sector. In addition, using EuroVaQ 
data, I also explore for four of these countries if the threshold values reflect individuals 
willingness-to-pay (WTP). Last, the relationship between GDP per capita and the QALY 
thresholds are analyzed. I conclude that there is little coherence between the sectors, only one 
country report similar value. In addition the WTP presented in EuroVaQ is lower than both 
the transformed VSL and the QALY thresholds. The GDP per capita has a positive effect on 
the thresholds. The results imply that the two sectors value human life differently.  
 
Keywords: VSL, QALY, Threshold, Health, Transport 
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1. Introduction 
1.1 Background 
How much is a man or woman’s life worth? Most would perhaps instinctively argue that a life 
is priceless and that it is impossible to quantify in monetary terms. But reality shows that we 
are often not prepared to do whatever it takes to save a life. Resources in society are scarce 
and it is important to plan and evaluate how to best use the resources. There is a need of 
knowing how much we should spend in order to save a person and to maximizing individual’s 
utility. In the wake of scarcity of resources, economic evaluation has become an increasingly 
important part of economics and a powerful tool for governments and policymakers. 
Indirectly, economic evaluation is something individuals have done for ages; 
however the use of economic evaluation as an official tool is a recent development. 
Comparing costs and benefits and the use of cost-benefits analysis (CBA) was primarily 
initiated in the 80s by Ronald Reagan who in 1981 required a regulatory impact analysis 
(RIA) for all major economic decision in the American government (Boardman et al 2014). 
RIA is a type of CBA and with the CBA the policymakers could justify its decisions. After 
the Reagan’s initiative the use of economic evaluation and CBA has become praxis in many 
countries for almost all major economic decision (Boardman et al 2014).  
 To enable the state to redistribute resources efficiently across sectors the use of 
economic evaluation is good in theory; decisions will be made on the same basis in all sectors 
creating an efficient distribution of resources. The purpose of economic evaluation is to 
choose the best decision on a monetary basis that balances the resources available against the 
need. It is a common view that the responsibility of the state is to distribute the resources 
efficiently (Hindriks et.al 2013). Assuming that the state should strive for an equal efficient 
distribution of resources it is crucial that all sectors within the state value human life in a 
similar manner.          
However, measuring costs and benefits is complex, especially measuring the value of 
a human life and assigning a monetary value to a human life. Assigning monetary value or 
putting a price on a person is not only complex, it is also considered as a moral problem. 
Hansson (2007) argues that human lives and money are incommensurability; assigning values 
to human life should be for calculative purposes only (Hansson 2007). However, in practice 
this is not always the case. In many countries there is monetary value on human lives that is 
used to evaluate decisions.  
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Two sectors where this phenomenon is present in is the transport and health sector 
(KCE 2008, Cost-Benefit Analysis 2012, Baguelin et al 2010, SafetyNet 2009 and Influensan 
A(H1N1) 2009). In this thesis I will focus on these two sectors and their valuation of human 
lives. 
 In transport economics it is common to use value of statistical life (VSL) to monetize 
human lives. The VSL is a value of an average person and what that person’s full life is worth 
(Boardman et al 2014, Hultkrantz et al 2008, and Andersson et al 2011). How to monetize the 
VSL has varied through time. In the 70s the human capital method was primarily used 
(Hultkrantz et al 2008 and Andersson et al 2011). The increasing use of CBA following 
Reagan’s initiative also developed the ways of monetizing VSL and Stated preference (SP) 
methods became frequently used and especially the contingent valuation (CV) (Boardman et 
al 2014, Andersson et al 2011 and Hultkrantz et al 2008)..  
 VSL can be linked to Quality-Adjusted Life-Year (QALY) which is the most 
common measure in health economics. QALY measures both morbidity and mortality and is 
designed as a utility measure where the quality of life is viewed in a scale ranging from 0-1 
(Boardman et al 2014, Burström et al 2013, Sassi, 2006 and Hultkrantz et al 2012). However, 
following the boom in CBAs, a need of monetizing QALY, like the VSL, emerged. Medical 
spending accounts for a substantial portion of the government spending, so it has become seen 
as increasingly important to economically evaluate the decisions in the health sector. To 
monetize QALY, Willingness-To-Pay (WTP) is commonly used. The first attempts to 
estimate the monetary value of a QALY using WTP was made in the 70s. Since then, 
countless other studies have been conducted resulting in a wide range of answers (OECD 
2012). One of the most recent and biggest projects so far was the EuroVaQ project. The 
project was an EU funded project aiming to develop robust methods to analyze the WTP for 
several European countries with a sample of over 40 000 individuals (EuroVaQ 2010). Even 
though there seems to be an uncertainty coming to estimate the value of a QALY, threshold is 
being used in many countries. The thresholds are not official in all countries (KCE 2008), but 
are still used as a tool to evaluate decisions (A(H1N1) 2009, KCE 2008 and Cost-Benefit 
Analysis 2012). 
 QALYs can also be calculated from the VSL (Abelson 2003 and Boardman et al 
2014). The transport sector and the health sector are two important sectors handling and 
evaluating major projects and who uses two different measures in order to put a price on a 
human life. The value of a human life should be the same within a country since it should 
represent the preferences in that country (Loomes 2002). Since it is possible to calculate the 
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value of a QALY value from the VSL it is also possible to compare the value of human life 
set in the transport sector to the value set in the health sector.  
 
1.2 Purpose 
I take my departure from the assumption that the purpose of economic evaluation is to enable 
the state to distribute its resources in an efficient manner. The aim of the thesis is to compare 
the values used by official authorities in the transport and health sector in order to see if there 
is coherence between the sectors. If it turns out to be a different valuation between the sectors 
the implication could be that the economic evaluation is not an efficient tool. Using data for 
VSL from the SafetyNet (2009) project and threshold values for QALYs the comparison will 
be done for 10 countries using an approach suggested by Boardman et al (2014) and Abelson 
(2003). Four of these countries were also a part of the EuroVaQ (2010) project. In the four 
countries there is a possibility to compare the WTP from EuroVaQ project to the values used 
in the transport sector as well as the health sector. The WTP could give a hint if the values 
used in practice for economic evaluation is reflected in the preferences of the population. 
Lastly an analysis of the wealth, measured as GDP per capita, and QALY threshold will be 
conducted to see if higher wealth gives a higher threshold.  
 The thesis will answer the following questions: 
 
- Is the value of human life the same in transport and health sector? 
- Does the value of the human life reflect the preferences in the population? 
- Does higher wealth result in a higher value of a QALY threshold? 
 
While the main body of the literature within health economics focuses on the WTP for a 
QALY and the methodological problems concerning the measurement, little attention has 
been directed towards the differences between the health sector and the transport sector and 
their ways of measuring human life. Differences in the value of a human life between the two 
sectors could potentially lead to an inefficient distribution of resources in the society. 
 
1.3 Disposition 
The thesis is organized in the following g way; in section 2 the theory will be presented. An 
introduction the concept of VSL and QALY as well as the approach used in order to 
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transform the VSL into value comparable to the value of a QALY will be presented. Section 3 
presents the method used in the thesis, the data will also be discussed under section 3 where 
focus will lie on the references used for the VSL and QALY thresholds, since there is a 
presence of uncertainty. In Section 4 the results will be presented. Following section 4, 
section 5 is the discussions of the results. The discussion will deal with the implications of the 
results and the validity. Lastly a shorter conclusion will be presented.    
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2. Theory 
In order for policymakers to make correct decisions one must first ask, how do we decide 
what is the correct decision. To evaluate economics decisions there is several cost analysis 
tools at hand. The three mostly used are CBA, Cost-Effectiveness Analysis (CEA) and Cost-
Utility Analysis (CUA). CBA measures all cost and benefits and assigns it monetary values. 
The basic decision rule is if the benefits are greater than the costs then there is motivation for 
the policy. CEA is used when the objective is clear and the state seeks the most effective way 
to accomplish the objective. The use of cost-effectiveness ratio is common and will be more 
thoroughly introduced in section 2.4. Lastly the CUA is a way to analyze impacts without 
assigning monetary values to them. It could be due to the fact that it is difficult to assign 
monetary values to all impacts. Consequently the costs of the policy is compared to the utility 
gains, here the use of QALY is common. QALY is used without a monetary value and it is the 
gain in quality of life that is important (Boardman et al 2014). These three methods are the 
most common in economic evaluation. The focus for the thesis is however not to investigate 
these method but instead the monetizing of VSL and QALY. To be able to do that an 
introduction of the two concepts are necessary and also how they can be monetized.   
 
2.1 Value of Statistical life  
The VSL is a theoretical concept trying to estimate the benefit from saving a person’s life 
through an intervention (Boardman et al, 2014). If a policymaker is planning to build a road 
for bicycles and cars they have to decide if they should have separate lanes for the two. The 
benefits from building two separate lanes could be measured in how many lives it will save 
from fatal accidents. These lives saved must be put in monetary form in order to perform a 
cost-benefit analysis of building the two separate lanes. One way of doing this is to estimate 
the VSL. The VSL monetizes the benefits from the lives it will save. A high VSL will enable 
more expensive policies in order to save lives and hence a low VSL will lead to less 
financing. VSL is often used in order to evaluate infrastructure project, roads and railways 
and is a common feature in transport economics (Andersson et al, 2011). 
   
 
Andreas Nilsson  NEKP01 
9 
 
2.2 Quality-adjusted life-years  
In CUA it is common to use the measure of QALY or DALY (disability-adjusted life-years. 
This thesis will focus only on the QALY measure. The strength of this measure is that it 
reflects both mortality and the morbidity. In other words it reflects the quantity (mortality) of 
life, which can be the life-expectancy, but it also reflects the quality (morbidity) of life. The 
morbidity is the quality of the remaining life-years measured in a scale from 0-1 where 0 
refers to death and 1 refers to a state with perfect health. Where on the scale 0-1 a certain 
health state ends up in is calculated by assessing health-related quality of life (HRQoL) 
(Boardman et al, 2014). HRQoL reflects the quality part of QALY and can be measured with 
different methods. One of the most common is the EQ-5D method which is a questionnaire 
reflecting five dimensions. These five dimensions are: mobility, self-care, usual activity, pain 
and anxiety. The use of this questionnaire is widely accepted but can be criticized for a lack of 
coherence on what values that should be used on the scale. Hypothetical values used by NICE 
in Great Britain seems to be a high estimate compared to Swedish data based on a health 
survey (Burström et al, 2013). The EQ-5D method is closely linked to the health index 
method (HR) (Boardman et al, 2014). Boardman et al (2014) identify three other methods 
used to estimate the HRQoL value. These methods are: the time trade-off (TTO), standard 
gamble (SG) and health rating (HR). In the TTO method respondents are asked to compare 
and chose between different bundles of remaining life-years and the quality of those life-
years. One alternative is living fewer years but with high quality and the other is living longer 
but with lower quality. The SG method respondents are presented with different alternative 
with different outcomes and probabilities. It can be compared with having a surgery that will 
fully restore the health but there is a risk of complications from the surgery. In the last 
method, the HR method, respondents are asked to rate health states. Estimating the HRQoL is 
complex and the results from the methods vary a lot creating uncertainty for the QALY as 
well (Burström et al 2013). Also earlier studies has found that age and sex has a significant 
importance on the HRQoL suggesting that men have higher estimates than women and that 
older people value their health less than young (Dolan et al 1996).  
 
2.3 Monetizing VSL and QALY  
The VSL varies between countries and in studies. Exactly how it should be measured is not 
standardized. One of the most common ways to measure the VSL is using WTP for the VSL. 
The WTP can be estimated through different SP methods, which is a direct estimation. There 
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is also revealed-preference (RP) method which is an indirect estimation method where you 
analyze preference revealed in other markets (Hultkrantz et al 2008). CV method is one of the 
SP methods and also the most common in transport economics (Hultkrantz et al 2008). CV 
method is based on survey studies where the researchers present individuals with hypothetical 
questions and scenarios where the respondent are asked to state his or hers WTP or WTA 
(willingness-to-accept) for the scenario (Boardman et al, 2011).  
Methods used in order to estimate the value of a QALY is similar to the ones 
mentioned above. CV and WTP are most frequent used but other SP and RP method could 
also be used. It is also possible to discount the VSL to estimate the value of a QALY. The 
method of discounting VSL will be discussed in detail in section 2.3.3. A combination of CV 
approaches is used in order to estimate the WTP for a QALY in the EuroVaQ project, further 
discussed in the method section.  
 
2.3.1 Contingent valuation 
The CV methods are divided into three approaches; Direct elicitation, dichotomous-choice 
and discrete choice experiment. 
The direct elicitation, also called non-referendum, is straight forward and respondents are 
asked directly their WTP. However there are three ways it could be used in practice; open-
ended, close-ended and contingent ranking method. The open-ended is only stating the WTP. 
Close-ended include a specified amount presented to the respondent. The respondents are 
asked a specified amount until he or she agree on amount (if no, the specified amount goes 
down until yes, if yes the specified amount goes up until no). The procedure resembles to 
negotiations over price. The close-end way has a weakness in the first amount presented since 
it could affect the respondent. The third way, contingent ranking, is based on a ranking of 
good presented in monetary values. The WTP is then estimated from the ranking. The 
contingent ranking is sensitive to what alternatives are given and in what order since it can 
affect the respondent (Boardman et al, 2011).    
 Dichotomous-choice method, referred to the referendum method, is similar to the 
close-end way of direct elicitation. The respondents are asked if they are willing to pay a 
specific amount chosen by the researchers. Several amounts are presented and the fraction of 
respondents who agree is presented in a histogram, the answers being the respondents that 
agree on the specific amount. From the histogram the demand curve can be estimated and the 
area under the curve is the estimate of the WTP (Boardman et al, 2011).   
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 A discrete choice method focuses on the attributes of a certain good. Then the 
attributes of the good is changed with a price level attached (both good and bad changes) and 
the respondent is asked to select the preferred bundle of attribute. Usually implemented by 
multiple choice questions, note that the good can be abstract and referring to a health state. In 
that case the method is similar to the EQ-5D method which will be described in the QALY 
section (Boardman et al, 2011).   
 Even tough CV method is the most common method today it still faces some 
critique. First there is the difference of WTP and WTA where WTA usually gives a higher 
estimate compared to WTP. WTA reflect an individual’s willingness to separate from 
something he or she already possesses. Individuals tend to value goods in their possession 
higher than goods they do not possess, which is reflected in the WTP. However, since WTP is 
the most used concept this is not an issue that I will focus on in this thesis. Other issues with 
CV that could give rise to bias results are Hypothetic bias, warm glow, strategic response, 
framing and embedding effects. The best solution is simply to devote a lot of time and effort 
to create a good survey, understandable for the respondents (Kling et al 2012 and Boardman 
et al, 2011).  How the structure of the questionnaire is built up is important, especially how 
risk and uncertainty is presented. Kahneman et al (1979) presented the concept of prospect 
theory in 1979.  What they found is that individuals are risk-seeking when it comes to 
avoiding losses and risk-averse for gains. Using this theory can explain some differences in 
the WTP from different studies since individuals can be willing to pay differently for health 
gain compared to avoid health losses.  
 There have been attempts to standardize the SP methods; one example is after the oil 
catastrophe in Alaska in 1989 when the oil tanker Exxon Valdez ran aground. There was a 
need of monetizing the impacts on the environment following the accident, SP methods where 
used but came under heavy criticism. Because of this the National Oceanic and Atmospheric 
Administration (NOAA) formed a panel in 1992 whose main task was to put up guidelines in 
order to standardize the SP methods. In this panel well known economists where represented, 
such as Arrow, Solow and Leamer, to name a few (Kling et al, 2012). Despite these 
guidelines recent studies still finds a wide range of values of the WTP for the VSL suggesting 
that there is still some issues of valuating with WTP and SP methods (Boardman et al, 2013). 
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2.3.2 Revealed Preferences and Human Capital method 
Another method based on surveys is a wage-risk approach. The wage-risk is a RP method.  
The approach focuses on scenarios which are easier to grasp for individuals than other WTP 
questions. Instead of stating the WTP ones is asked to state how much more wage they 
demand in order to increase their job related risks. Then one can use these preferences in 
order to calculate their WTP for a VSL or the value of a QALY (Boardman et al 2014). 
 It is also possible to use the human capital method to estimate the VSL value. 
However the method is becoming less popular. The method is based on calculating the 
expected earnings for individuals. The problem with the method is its shortages in explaining 
individuals’ preferences (Andersson et al, 2011 and Hultkrantz et al 2008). While it is 
becoming less popular used by itself it is sometimes used in combination with WTP. By 
incorporating the human capital method with WTP one can also analyze the production loss 
for the state when a person dies as well as WTP (Andersson et al 2011). In the transport sector 
material and medical costs can also be added in association with accidents to the VSL 
(Trawén et al, 2002). Sweden is one of the countries that add these features to its VSL. The 
VSL for Sweden contains both an aspect of the WTP and the loss of production for an average 
person as well as the material cost. The US and Great Britain also add an amount for the 
material cost as well as the medical cost (Andersson et al, 2011). Norway uses the loss of 
production value in their VSL (Cost-Benefit Analysis 2012). 
 Using SP method and the RP method can give a wide range of answers. The 
variation between studies can hence be explained through different methods and not 
necessarily different preferences. For a more detailed overview of differences and how to use 
SP and RP in a correct manner, see Harrison (2006). 
 
2.3.3 Discounting VSL and the concept of VLY 
Another way of estimating the monetary value of a QALY is to use the VSL. Using an 
approach presented by Abelson (2003) and Boardman et al (2014) gives the opportunity to 
use the VSL and discount it to create the value of QALY. First the concept value of a life-year 
(VLY or VOLY) need to be introduced. VLY is a constant value reflecting the value of one 
year based on the VSL value. The VSL is discounted by an annuity factor which gives the 
VLY. VLY is denoted in equation 1 below: 
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Equation 1: Value of a life-year (VLY), Source: Boardman et al (2014) and Abelson (2003) 
 
Assumptions needed are that the VSL need to be constant for the remaining life-expectancy, 
denoted by     .          is the annuity factor where r is the discount rate and T-a is the 
remaining life years. VLY can be assigned weights in order to widen what it can measure. 
Health weights denoted by wt can be applied; making the VLY comparable to the QALY 
relationship is shown in equation 2 below:  
 
            
Equation 2: Quality-adjusted life-year (QALY), Source: Boardman et al (2014) 
 
The strength of the QALY measure compared to the VLY is the quite high probability that not 
all years are spent in the same health state (Boardman et al, 2014). Also your health stock is 
likely to decline over time (Grossman. 1972). When the health stock declines the QALY 
value will also decline. To evaluate interventions and policies it is important to note the 
declining health stock and compare the expected discounted QALY over time (Boardman et 
al, 2014). However, since economic evaluation focuses on a specific point in time the 
declining health stock is not an issue.  
 
2.4 Incremental Cost Effectiveness Ratio  
CEA is a common valuation method in health economics. CEA is useful when the target for a 
policy is clear and well defined and what is left to decide is which alternative to chose. The 
main difference between CEA and CBA is that in CEA the benefits are not monetized. Instead 
focus lie on measuring the cost and the effectiveness of the policy. The effectiveness can be 
lives saved form vaccination, or in education it might be test results. The costs and 
effectiveness are then compared in a ratio; the ratio is called ICER or Incremental Cost 
Effectiveness Ratio which is shown in equation 3 below:  
       
     
     
 
Equation 3: Incremental Cost Effectiveness Ratio (ICER), Source: Boardman et al 2014 
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ICER is the ratio used where C denotes costs and E denote effectiveness. The sub indexes of i 
and j denote the different options (Boardman et al, 2014).  
 However, if one would look only at the cost-effectiveness ratio (CE) where one focus 
on the cost and effectiveness it is possible to estimate the cost per life, if the effectiveness is 
measured in saved lives (Boardman et al, 2014). It could also be the case that policies within 
the health sector look at saved QALYs, if there is a threshold value or benchmark of the 
QALY we can in theory measure the benefit in monetary form. This was done in the CBA of 
the swine flu vaccination in Sweden 2009 conducted by Socialstyrelsen and MSB (Influensan 
A(H1N1), 2009). In Great Britain a similar study was made by Baguelin et al (2010). In 
analysis like the ones mentioned above with QALY as an effectiveness measure, we are 
moving from CEA towards CBA. In CBAs, threshold values become an important decision 
tool in the health sector when it comes to measure befits. In the CBAs the effectiveness can be 
measured as QALYs gained, that is how many QALY with the score 1 was gained by the 
intervention. This reflects a weight of 1 in equation 2. 
 
2.5 Health care expenditure and GDP  
Medical expense has risen dramatically the last decades as a share of GDP (Jones 2002). 
Williams (2004) argued that the use of GDP should be given more importance in the 
estimation of QALY thresholds because the threshold should reflect the average wealth of the 
population. Wealth, measured as GDP per capita, and health expenditure has been found to 
have a strong relationship in earlier studies (Gerdtham et al 1991) so it is likely to be a 
relationship between the value of a QALY and GDP as well. Since the threshold values are 
used in the decision process within the health sector it is likely that an increase in the health 
care expenditure is reflected in the threshold values. Also, when it comes to income and 
health there is a large literature on which way the causality goes. The demand for health is 
likely to increase as income goes up. The income increases as the health level increase 
(Rivera et al 1999 and Devlin et al 2001). However, discussion regarding the causality is 
beyond this thesis.   
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3. Method 
The aim of the thesis is to compare the valuation of human life in two important sectors of the 
society, the health sector and the transport sector. Both are crucial for a modern welfare 
society. As mentioned in the theory section health sector use the value of a QALY as a 
measure for life and transport use VSL. These measures cannot be compared directly since 
VSL is a measure for all remaining life years and the value of a QALY only reflect one year. 
However, it is possible to discount the VSL value and transform it, making it is possible to 
make a comparison. However, some assumptions are necessary regarding discount rate, life 
expectancy and weights. The base for the calculations is the one presented in the theory 
section by Boardman et al (2014) and Abelson (2003) (see equation1 and 2). Note that the 
thesis is not a test of the approach presented in the theory section. It is assumed that the 
approach is correct. With the assumptions, however, comes a certain degree of uncertainty 
which could alter the results and make it difficult to interpret. A short discussion of the 
uncertainty and how it is dealt with is presented below. Discussion regarding the data will is 
presented in section 3.4, where the discussion of the VSL and the thresholds values of a 
QALY will be dealt with.  
 To follow Boardman et al (2014) and Abelson (2003) approach to calculate a value 
from the VSL that is comparable to the value of a QALY, there is a need to discount the VSL. 
The VSL is discounted with an annuity factor containing life expectancy and the discount 
rate. Discounting the VSL will lead to the VLY, which can be assigned weights. The weights 
can be from 0 to1 where 0 is comparable to death and 1 is perfect health state. Assigning these 
weights to the VLY make it comparable to the value of a QALY (see equation 2). For the 
reminder of the thesis the discounted VSL is called the transformed VSL. The transformed 
VSL is the value used in order to compare the value of a QALY and the VSL. In the two 
following section a detailed discussion about the life expectancy and the discount rate.  
 
3.1 Discounting VSL: Life expectancy 
The life expectancy is the expected remaining life years an individual have from birth. 
However VSL is calculated for an average person. The average person’s age is not defined 
but is recommended to be 40 year by EU (Cost-Benefit Analysis, 2012) and it is also most 
commonly used (Abelson 2003). Also later research has also found an inverted U-shaped 
relationship for valuation of VSL and age. There are some differences in different age 
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categories and it seems to increase up to the age o around 40. After the peak it decreases 
suggesting it has a peak at around 40 (OECD, 2012 and EuroVaQ, 2010). The results of the 
peak around 40 also support the usages of an age of 40 as average person since it is the max 
VSL that is interesting to capture. For the first calculations made in this thesis the average 
person will therefore be at the age of 40. But, as mentioned, there is no standard value and 
even though research and recommendations suggest the use of 40 it is not certain that all the 
countries in this study use that age. To deal with problem of the average person several 
calculations will be made for different age of average person, ranging from 30 up to 40. These 
calculations will be used to construct a confidence interval. The calculations will be integrated 
with the uncertainty of the discount rate; this will be discussed later.  
 There is also another issue with discounting VSL with life expectancy. The main 
goal is the end up with a value of a QALY, one can argue for the use of quality-adjusted-life-
expectancy (QALE) (Sassi, 2006). However such data is not available for the countries and 
the data that is available is not calculated in the same manner in different countries, so regular 
life expectancy will work as a proxy. If data was available for QALE it could give other 
results than using the remaining life years.  
 
3.2 Discounting VSL: Discount rate 
What discount rate to use has an influence on the results and it is not straight forward to what 
rate one should use. A study by Bonneux et al (2001) regarding cardiovascular diseases found 
that a discount rate increasing from 0 % rate to 3 % could decrease the cost for an intervention 
with almost 9 times, when comparing the cost-effectiveness. It is clear that the discount rate 
matter, however using 0 % is not realistic. Boardman et al (2014) uses 3.5 % and Abelson 
(2003) use 3 % but there is no standard level of discount rate, there is a clear difference 
between the countries (EuroVaQ 2010). According to EuroVaQ (2010) data, which contain 
four of the countries also investigated in this thesis, the discount rate varies from 1.5 % to 4 
%. Great Britain use 1.5 %, Netherlands have 2.5 %, Sweden has 3 % and Norway has 4 %. 
With that said, Baguelin et al (2010) used 3.5 % for a CBA in Britain for the swine flu, so 
there is uncertainty about the discount rates presented in EuroVaQ.  The discount rate also 
varies between the sectors. Hultkrantz et al (2012) findings suggest that the Swedish health 
sector uses 3 % where the transport and traffic sector uses 4 %. The calculation in the thesis 
made in order to transform VSL to value comparable to the value of a QALY uses two 
different values of the discount rate in order to deal with the uncertainty. The values are 3 % 
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and 4 %; this is motivated by the fact that Boardman et al (2014) uses 3.5 % and Abelson 
(2003) use 3 %. Also Norway uses 4 % which motivate the high value of 4. I will be using 3 
% since having a wider range of different discount rate can actually cause more problem than 
it solve. Netherlands and Great Britain have according to EuroVaQ rates below 3 %, but I 
cannot be certain that they actually use those rates, which are evident in Baguelin et al (2010), 
and there is a lack of information of the other countries. Hence, it would be like shooting in 
the dark in order to estimate the discount rates for the other countries. Therefore only the two 
values will be used. Note that the use of two values only deal with the issue to a certain 
extent, it will not solve the problem.   
  
3.3 Comparison method 
To be able to compare the VSL and value of a QALY a 95 % confidence interval will be used. 
The interval of the transformed VSLs will then be compared to the threshold values from the 
health sector. If the QALY threshold lies within the 95 % interval then it implies that the VSL 
and QALY and hence, a human life, is worth equally in the two sectors. The confidence 
interval acts as a sensitivity factor as well, there is uncertainty in the discount rate and how 
the life expectancy should be used. To some extent solve the issue two discount rates will be 
used, 3 % and 4 %. Also a life expectancy with a 11 years span is introduced starting with an 
average person with the age 30 going up to 40, as has been identified as the age where the 
values is the highest (OECD 2012 and EuroVaQ 2010). The procedure gives a total of 22 
observations for each country and the CI is constructed from these 22 observations. The 22 
observation comes from 11 observations with 3 % and 11 with 4 % discount rate. The 
procedure gives more credibility to the approach suggested in the theory as how to discount 
the VSL (see equations 1 and 2). A calculation with the base year of 40 and the discount rate 
of 3 % for all countries is also presented. Using the results from the EuroVaQ project for the 
countries that are available, the WTP for a QALY is also compared to the threshold values as 
well as the transformed VSL.  
 In addition a regression is performed to analyze the relation between GDP per capita 
and the QALY thresholds. Both the QALY threshold and the GDP per capita are in 
logarithmic form. Following the regression a linear prediction is conducted of the threshold 
values. Note however that there are only 10 observations, which is the number of countries in 
the dataset. This makes the conclusion of the results weak, the results will be interesting but in 
order to do significant interpretations of them there is a need of a larger dataset. As for the 
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causality problem with health and wealth I cannot conclude in which direction it may go. That 
is beyond the thesis. However, with the results it is still possible to analyze if the threshold 
values are too high or low compared to the wealth level.                        
 
3.4 Data 
The data used in this thesis comes from various sources and must be handled with care. In this 
section the data will be presented, where it is from and also its limitations and shortcomings. 
As the reader will note, some of the data is not the most trustworthy, however the access to 
data is limited which must be kept in mind. The countries in the data set are Australia, 
Canada, Finland, Great Britain, Ireland, Netherlands, New Zeeland, Norway, Sweden and 
United States. The reason for choosing these countries is the access of QALY thresholds and 
VSL used in practice in economic evaluation. The year for used as base year in this study is 
2008. This is motivated by the fact that the VSL values where collected at that point 
(SafetyNet, 2009). There is a need for a reference year in order to have the same price level 
and calculate the life expectancy. However, it is not clear when the VSL value are calculated. 
Also it is not certain when the QALY thresholds were calculated.  
 
3.4.1 Life expectancy and PPP adjusted GDP per capita 
The calculations are based on the average person with the age of 40, and a range calculation 
between 30 and 40. The remaining life years are hence the expected life expectancy from the 
age of 40 to the death. The data on life expectancy is collected from the World Bank (World 
Bank, 2014). The year used as base year is 2008. An overview of the life expectancy and the 
data used for calculations are available in the appendix, table 5.  
 As 2008 is used as the base year the currency must be in 2008 years currency and it 
has to be the same for all countries. The VSL values were presented in Euros and most of the 
QALY threshold value is presented in domestic currency. In the calculations all values are 
converted to PPP adjusted US dollar for 2008 making it easy to interpret the results. Exchange 
rates and GDP per capita was taken from OECD data (OECD, 2014). GDP per capita for all 
countries is presented in the table 6, available in the appendix.  
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3.4.2 VSL 
Official data on VSL is scarce and the data that do exist is limited in the way it has been 
calculated. The data used in this thesis is from the SafetyNet (2009) project. The report was 
funded by the European Commission, Directorate-General Transport and Energy. The project 
gathered information on official values from 23 countries. Unfortunately there is no 
information on how the values were estimated and which methods used. The countries 
investigated in this thesis are among those 23. The uncertainty of the data and the methods 
used to estimate the VSL is a problem but as mentioned there are few other sources of VSL 
and these values are official according to SafetyNet (2009). As long as it is the official values 
it serves the purpose of the thesis.  However it is worth to note that there is likely to be a 
difference in how to estimate between the countries. Also, who is responsible for the official 
values differs between the countries. In several countries it is the road or traffic 
administrations that are responsible for the official VSL value (Andersson et al, 2011, 
SafetyNet, 2009 and Cost-Benefit Analysis, 2012). The lack of data is also showed by Trawén 
et al (2002); they conducted a survey in order to establish the official VSL values, only 11 
countries responded. The VSL values for the ten countries of interest are available in table 7.  
 
3.4.3 QALY Thresholds 
The access to VSL values is limited although official. The data for QALY thresholds are also 
scarce and are in addition often not official. In some of the countries the threshold is from 
official sources like government institution, however, the threshold is not an official 
recommendation. With that said, it is clear in many cases that even though it is not official it 
is still being used in comparisons in CBA by official institutions. One example is the Swedish 
value of 600 000 SEK which is not official, still it is being used by official institutions 
(Influensan A(H1N1), 2009). In Norway it is the same scenario, there is no official threshold 
but a figure of 500 000 NOK is commonly used (Cost-Benefit Analysis, 2012). Due to the 
lack of data and lack of official thresholds the data set consists of 10 countries. Some of the 
threshold values are in intervals, since the focus of the thesis is to investigate the value of a 
human life I only present the top value. One can argue for an average number of the interval, 
however, the top value should indicate that some policies have been accepted at that threshold 
which means that a life could be valued at those levels. It is interesting to investigate what is 
the maximum we are willing to pay for a life. 
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 The thresholds number is presented in table 11 in the appendix. In table 11 the 
source for every threshold number is also presented and comments on the values as well as 
the source.  
 
3.4.4 EuroVaQ 
The EuroVaQ project was initiated 2007 and lasted until 2010. It was an EU funded project 
consisting of 10 countries and approximately 40 000 individuals. The main goal of the project 
was “to develop robust methods to determine monetary value of a QALY across a number of 
European member states” (EuroVaQ 2010, p.7). In the process the WTP was also calculated 
for these 10 countries using SP method based on surveys. Two main approaches was used, 
namely a chained approach and a direct approach, individuals from the sample of 40 000 
where randomly assigned to one of the two approaches. 
 The direct approach is straight forward and the survey questions simply asked how 
much are an individual willing to pay in order to avoid a health problem. Note that all health 
problems presented in the questions lasted for at least one year, also, little risk were assigned 
to the health problems. The advantages with the direct approach are that it is straight forward, 
making it easy for the respondents to grasp the questions. However, some critique may be put 
forward regarding the range of answer with some very high and some very low and in some 
cases zero, indicating that respondents has not fully understand the magnitude of the question. 
Some respondents also stated zero as their WTP as they argued that it was the state’s role to 
pay for treatment, these values were recorded as missing values in the sample.  
 The chained approach was done in two steps. The motivation behind the chained 
approach is to keep health changes at a minimum to decrease the chance of a budget 
constraint bias, likely to be present in the direct approach where the health problems were 
substantial. However, in order to make the method work, one need to assume that the WTP 
for a QALY is linear since the small health increase is multiplied up to a full QALY. Hence 
there is a need to assume linearity. In the first step two health states were presented, green and 
yellow, to the respondent. The green health state dominated the yellow but both health states 
have small changes in QALY. The health states are presented in the EQ-5D form (see section 
2.2) and the respondent’s utility for the two health states are determined. The utilities were 
determined by the TTO method or the SG method, which method used was randomized 
through 8 different versions where half of the 8 were determined by SG method and half by 
the TTO method. Then risks are introduced together with probabilities of being in the health 
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state for a certain amount of time (six scenarios). The WTP is based on the respondents WTP 
to avoid the risk of being at the health state. The respondents were given 15 different amounts 
in random order then order these amounts in the following categories: definitely would pay, 
definitely would not pay and unsure. The highest amount order in the category, definitely 
would pay was taken as the WTP. However if the respondent were willing to pay more than 
they were asked to state that specific sum, then the specific sum was used as the WTP for the 
QALY. Again, respondents who argue that the state should pay were removed from the data.  
 EuroVaQ was an internet based survey and has the problem, like many surveys based 
project, of a low response rate. In the four countries analyzed in the thesis, none have a 
response rate over 20 % of the invitations sent out. The low response rate creates a problem of 
bias and the results should be handled with care. In the thesis the results from the chained 
approach will be used due to the strength of the method. The means from the two health states 
(green and yellow) and the risk-variant questions will be added and a mean for all will be 
calculated representing WTP for a QALY. I will use the trimmed data where the top 1 % 
outliers are removed. The respondents who stated their WTP to be zero is also removed in the 
trimmed results. In the appendix the WTP is presented as well as the response rate. Also, the 
six scenarios and the changes in QALY are presented. In table 8 the health states are 
presented, in table 9 the WTP and response rates are presented and in table 10 a more detailed 
overview of the WTP is presented.    
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4. Results 
The following section presents the results in four tables. In connection to each table there is a 
short summary of the findings.  
 In table 1 the value of human life is presented. For the transport sector the VSL has 
been transformed using 3 % as a discount rate and 40 year as the average person. The last 
column present the QALY threshold value used in the health sector.  
Table 1: Value of Human life 
Country VSL  Annuity Transformed VSL QALY Threshold 
Australia 1147568 23.53 48775 51384 
Canada 1354557 23.28 58192 64809 
Finland 1224491 22.98 53277 76284 
Great Britain 2026118 22.99 88118 33706 
Ireland 1125755 22.85 49263 47292 
Netherlands 1674168 23.19 72192 94975 
New Zeeland 1638714 23.22 70572 13416 
Norway 2603086 23.29 111758 57129 
Sweden 1878992 23.44 80156 68389 
United States 3066584 22.47 136457 100000 
All numbers are in US dollar, the average person’s age is 40 years, discount rate is 3% 
As can be seen in table 1 there is substantial differences between the transformed VSL and the 
QALY thresholds in several countries. Australia, Canada and Ireland have quite similar 
values. Looking at New Zeeland the transformed VSL is five times as big as the QALY; this 
is the country with the largest difference. Note the wide range of results with countries both 
being substantially above and below. Note that the United States has both the highest 
transformed VSL and the highest QALY threshold.   
 In table 2 the confidence interval from the different approaches of discounting the 
VSL and creating the transformed VSL is presented, the confidence interval level is 95 %. 
The seventh column presents the QALY threshold values. The third column presents the mean 
of the transformed VSL from the 22 observations. 
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Table 2: Confidence Interval, QALY threshold and WTP 
Country Observations Mean Standard  
error 
95 %  
CI Lower 
95 %  
CI Upper 
QALY 
 Threshold 
WTP per 
QALY 
Australia 22 56867 1051 54680 59054 51384 - 
Canada 22 67125 1241 64543 69707 64809 - 
Finland 22 60680 1122 58346 63013 76284 23525 
Great Britain 22 100404 1856 96542 104266 33706 - 
Ireland 22 55787 1031 53641 57932 47292 - 
Netherlands 22 82963 1534 79772 86154 94975 25295 
New Zeeland 22 81206 1501 78083 84330 13416 - 
Norway 22 128996 2385 124034 133957 57129 41455 
Sweden 22 93113 1722 89532 96694 68389 30130 
United States 22 15196 2810 146120 157809 100000 - 
All numbers are in US dollar, the confidence interval based on an average person ranging from 30-40 years old 
and two different discount rates 3 and 4 % 
The results from table 2 support the results from table 1 when it comes to Canada, which is 
the only country which has a QALY threshold value that falls within the transformed VSL 
confidence interval. For the two other countries in table 1 that showed promising results, 
Australia and Ireland, the results now indicate that there is a lack of coherence between the 
sectors. Again, New Zeeland is the country with the biggest differences between the sectors; 
also Great Britain shows indication of substantial differences. Even though results from the 
QALY thresholds are both under and over the CI it seems to be a tendency that the QALY 
threshold value is lower than the transformed VSL. Of the ten countries, seven has lower 
threshold values, one is within the CI and two have higher values, namely Netherlands and 
Finland.   
 The last column present the results from the EuroVaQ report. The results only cover 
four of the ten countries, Great Britain, Netherlands, Norway and Sweden. Further details 
about the numbers from the EuroVaQ report are available in the data section and the 
appendix. Interestingly the results from the EuroVaQ for all the countries have values that are 
lower than both the QALY threshold and the CI lower bound. Norway presents the highest 
WTP whereas it only reports the third highest QALY threshold.  Netherlands who reports the 
highest QALY threshold of the four have the second lowest WTP. Excluding Netherlands 
from the results, suggest that transformed VSL has the highest value followed by the QALY 
threshold and the WTP for a QALY has the lowest monetary value in all countries.   
In table 3 a simple regression of the logged value of QALY thresholds and the 
logged GDP per capita is presented. As has been mentioned before there are only 10 
observations, so the statistical interpretations of the results are limited. From the regression 
the elasticity is estimated and it is above 1, which means that 1 percent increase in GDP per 
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capita increases the QALY threshold more than 1 percent. From the regression a linear 
prediction of the QALY threshold values is estimated which is displayed in table 4.  
Table 3: Regression 
Variable  
loggdp 1.933** 
 (0.834) 
constant -9.644 
(8.859) 
R-squared 0.40 
Observations 10 
Standard error in parenthesis, ** P < 0.05,  
Estimations made in STATA 10 
As can be seen in table 4 the prediction of the QALY thresholds is presented. The fifth 
column presents the real threshold values. Several of the threshold values falls within the 
predicted confidence interval estimated from the GDP per capita (Australia, Canada, Great 
Britain, Ireland, New Zeeland, Norway Sweden and United States).  
Table 4: Prediction of QALY threshold 
Country Linear Prediction 95 % CI Lower 95 % CI Upper QALY Threshold 
Australia 49155 34238 70573 51384 
Canada 51256 35983 73014 64809 
Finland 46556 31882 67989 76284 
Great Britain 43095 28490 65186 33706 
Ireland 56612 39724 80684 47292 
Netherlands 58697 40901 84246 94975 
New Zeeland 27649 13079 58448 13416 
Norway 116996 50046 273512 57129 
Sweden 50248 35164 71804 68389 
United States 73829 46065 118326 100000 
All values are in US dollar, Prediction made in STATA 10 
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5. Discussion 
In this section a discussion of the results and their implication is presented. The validity and to 
what extent the results are meaningful is in focus, including the problems with uncertain 
sources and methods. The discussion will take it starting point from the data since that is a 
crucial part of the thesis. 
 Dealing with human life is complex in many ways. Ignoring the moral aspect of 
assigning monetary value to human lives, there still remain obstacles. In transport and health 
economics the use of monetary values of human lives is used in economic evaluation but it is 
used in different ways. Transport use the VSL and health use QALY. The VSL data used in 
this thesis is from the EU funded project SafetyNet (2009), where they present the official 
values used within the transport and traffic sector. Exactly how the data is extracted from the 
individual countries and how it has been estimated in the individual countries is not detailed. 
Neither is it obvious if the VSL is actually used in practice. However, some confirmation of 
its practical use is made by the Norwegian ministry of finance for some countries (Cost-
Benefit Analysis 2012), indicating that the values presented in SafetyNet (2009) are actually 
the VSL used in practice. The origin of the data is however likely to differ from country to 
country. In Norway the numbers is said to origin from the 1980s and the human capital 
method, the same can be said for Sweden (Cost-Benefit Analysis 2012 and Andersson et al 
2011). Even though the values and method differs between countries they seem to be 
integrated to a certain degree since it appears to be common to make reviews of other 
countries values in order to make own estimations (Trawén et al 2002). To sort out the VSL 
complexity would require a research project by itself and it is not within the scope of this 
thesis.  I assume the values from SafetyNet (2009) as the ones used in practice for all the 10 
countries used in the data set. This of course affects the validity of the results in a negative 
way but it is necessary in order to reach a conclusion. 
 So, there is reason to question the data on the VSL, however, there is even more 
issues with the QALY values. In the health sector there is clear lack of transparency when it 
comes to assigning monetary values to human life. This viewed is shared by Abelson (2003), 
which is why he introduced the approach used in this thesis. It is clear that it is an area that 
requires delicacy as to how economic evaluation is performed. Unfortunately the development 
has created a situation where there is a lack of official values in almost all countries. In 
Sweden, for example, official reports refer to a value of the QALY which is estimated through 
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unofficial interviews with the Swedish dental and pharmaceutical benefits Agency, TLV 
(Influensan A(H1N1) 2009). As KCE (2008) highlight, it seems to only be Great Britain and 
NICE who has explicit value of a QALY threshold. Norway’s ministry of finance says that 
“Health services will often compare the estimated cost per QALY to a threshold of NOK 500 
000 per QALY” (Cost-Benefit Analysis 2012, p.163). The terms “often” and “usually” is to a 
large extent accompanied with QALY threshold. With exclusion from NICE, no health 
service agency seems to have the accountability that comes with assigning a threshold value 
to the QALY. Despites this fact it is constantly used in economic evaluation concerning health 
policies (Influensan A(H1N1) 2009, Baguelin et al 2010, KCE 2008 and Cost-benefit 
Analysis et al). The origin of the “unofficial” values is as a result unclear. Since no health 
agency takes responsibility of the threshold and since there is no official values, it is also 
difficult to determine if the numbers are realistic and reflects the WTP of the population. 
Which has been noted by Braithwaite et al (2008) who finds that the value of a QALY 
thresholds used in United States are probably too low, they also question the lack of scientific 
proof and methods used in order to estimate the US threshold. 
 There is also the issue regarding how the threshold values should be used. In Great 
Britain the threshold value is not used as a basis for budget decisions. NICE use the threshold 
value to allocate within a fixed budget. Then there is a need to evaluate both the health gained 
and the health forgone by redistributing. Introducing WTP does not take the health forgone 
into consideration (Claxton et al 2013). As the thresholds takes into account the loss of 
QALYs as well as the gain it is not certain it reflects the public WTP (McCabe et al 2008). 
The scenario in Britain might apply in other countries as well and be a part of the explanation 
of the results. However, the threshold set by NICE is used in CBAs, as can be seen in 
Baguelin et al (2010), so it is still motivated to analyze the threshold. Also, even in Britain 
voices has been raised to have a wider transferability of the monetary value of life between 
sectors (Loomes 2002). Although, as McCabe et al (2008) and Claxton et al (2013) note, 
transferability should in that case be used in the setting of the budget, not when the budget is 
fixed as it is within the NICE. The way NICE uses the threshold values could be the same for 
other countries. If all threshold values are used in a similar manner as by NICE, then the 
differences between the two sectors could be explained by the different practical use of the 
value of a human life.  
 The WTP of the population was a task that EuroVaQ tried to solve. Even though 
their main goal was to develop strong and robust method of estimating the WTP of a QALY, 
the project also estimated the WTP for several countries, including four that is analyzed in 
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this thesis.  The new methods used in the EuroVaQ may very well be superior to earlier 
studies, however the low response rates of the survey is a problem. “The goal of most 
empirical economic research is to overcome selection bias, and therefore to say something 
about the causal effect” (Angrist and Pischke 2009, p. 15). A way to solve the issue with 
selection bias, which can alter the results, is to have randomization (Angrist and Pischke 
2009). In the EuroVaQ project the survey was issued in a standard procedure, namely with the 
use of an internet survey provider, in this case the SSI (Survey sampling international). Their 
method might be random, but as noted, the low response rate (see table 9 for details) is likely 
to interfere with the randomization. Since there is a low response rate one must ask: who is 
answering the survey? And more importantly, who is not? Due to the low response rate there 
is a risk that the EuroVaQ result suffers from selection bias. The use of WTP is, in theory, a 
powerful tool but it is complex in practice, which is clear from the EuroVaQ project. This 
confirms the image of WTP raised by Olsen and Smith (2001), who points out the gap 
between theory and practice when it comes to WTP studies. Further on, the EuroVaQ is an 
open and transparent project but still suffers from issues, which raises questions on what 
problems might be present in the QALY thresholds values, as well as in the VSL results since 
those are considerable less transparent in their estimation and use.  So, it is clear there is a 
problem with the data presented in this thesis; however, it is important to note that this is data 
used in practice and it plays an important role in economic evaluation in health and transport 
sector.  
 The results presented in section 4 had some interesting features. There seemed to be 
little coherence between the health sector and transport sector. It was only Canada that 
showed similar results for the two sectors in both the comparison with average persons aged 
40 with 3 % discount rate and in the CI. The overall results suggest that the transformed VSL 
seems to have higher values. Also, introducing the WTP from the EuroVaQ their results is 
below both the QALY thresholds and the transformed VSL. If these results are valid then 
there might be an issue regarding the allocation of resources in the society. However, there are 
some uncertainties with both the data and the calculations that affect the validity of the result. 
First, as has been mentioned, the QALY thresholds are to a large extent, unofficial values.  So 
it is not certain that the thresholds are actually used. Second, the handle of the discount rate 
and the age of the average person are not perfect. It is a strong assumption that the average 
person in all countries is 40. Also, using life expectancy could give biased result. Thirdly, the 
discount rate is a similar problem as the age. The discount rate is probably around 3 % in most 
countries but it is likely to differ between the countries, which might also affect the results.  
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 For countries like Australia, Canada and Ireland, where the transformed VSL is 
reasonable close to the QALY threshold level it is impossible to say if there is a difference 
between the sectors. But for countries like Norway, Great Britain, New Zeeland and the 
United States it is likely to be a difference between the sectors since the values differ to such a 
large extent that it is not reasonable to explain the gap due to uncertainty of the calculations. 
For the four countries that were included in EuroVaQ it seems to be the case that the WTP for 
a QALY is lower than what is actually being used by the sectors. The issues with EuroVaQ 
have already been brought up and validity of those results is questionable.    
 The implication of the results is that it is likely there is not an efficient distribution of 
resources. With a higher value of human life in the transport sector, it could be the case that 
the transport sector is able to spend more money on project than the health sector, holding 
everything else equal.  In the long run this could be a problem with a skew distribution of 
resources. If the WTP from the EuroVaQ is close to the real WTP it is also the case that the 
true preferences of the population are not reflected in the value of human life. Leading to 
possibilities for the two sectors to spend more resources than what they should. The issues 
with different value of human life have not passed unnoticed.  In Norway they are aware of 
the problem and the problems associated. Their solution, presented by the ministry of finance, 
is to recommend a standard VSL of NOK 30 million that should be applied to all sectors. The 
solution to use VSL to calculate the QALY is the same solution proposed by Abelson (2003). 
In the United States the new patient protection and affordable care act even prohibited the use 
of QALY threshold within the health sector (Neumann et al 2010). However, Neumann et al 
(2010) criticized the same decision, “The use of explicit, standard metrics such as cost-per-
QALY ratios has the advantage of transparency and can help direct our resources toward the 
greatest health gains” (Neumann et al 2010, p.1496). While Neumann might be right that 
standard metrics might be a good tool for distributing resources efficiently, it is also clear that 
in reality there is little transparency in the use of QALY thresholds. So, the use of QALY 
remains debatable. Cleemput et al (2011) stress that threshold is insufficient as a measure for 
interventions and that an increase of transparency is desirable.  
 In addition to the comparison between sectors the relation between QALY threshold 
values and GDP per capita is analyzed. There is a large literature investigating the connection 
between health care expenditure and income levels as well as health and growth. The question 
of causality is however an issue, the direction of the relationship is debated. The analysis 
performed in this thesis will not provide a conclusive answer for this debate; however, it 
seems to be the case that higher wealth will lead to a higher value of a QALY. The elasticity 
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is found to be over one, consistent with earlier research (Gerdtham et al 1991). If Williams 
(2004) argumentation of a threshold value corresponding to the wealth level is solid, then it 
follows that some countries have a too high threshold value and some too low (see table 4). 
However, a majority of the countries have a threshold value that lies within the predicted 
confidence interval (see table 4). The results suggest that it seems to be the case that GDP has 
a significant role when it comes to explaining the threshold values. It is important to note the 
limitation on the QALY thresholds and wealth analysis due to limited dataset. The results are 
however consistent with earlier research and the results are in line with what is expected.  
 VSL and value of a QALY are important tools in economic evaluation in order to 
divide resources in an efficient manner. However, as has been shown, there is little 
transparency of the values and it seems that the values do not match each other between 
sectors.  
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Conclusion 
The main goal of the thesis is to compare the value of human life in the transport sector and 
the health sector. Valuating human life in a similar matter is a foundation for efficient 
distribution. This thesis show that when it comes to statistical life, the distribution might not 
work as desired. The results indicate a difference in the valuation of human life between the 
two sectors. Further on, the EuroVaQ results on the WTP for a QALY show that it is lower 
than the transformed VSL and the QALY thresholds, indicating that the value of a human life 
in the sector is not shared by the individual’s preferences. The results also indicate that wealth 
has a positive relationship with the QALY thresholds, suggesting that higher GDP per capita 
increase the QALY threshold. Also, there is indications that GDP per capita is possible to use 
in order to predict the QALY threshold. The limited dataset however makes the results 
unreliable and further research should focus on expanding the dataset and clarify how the 
VSL and QALY thresholds are actually used and how they are estimated.   
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Appendix 
1. Life expectancy 
Table 5: Life expectancy 
Country Life expectancy 2008 Life expectancy from 40 
Australia 81 41 
Canada 81 41 
Finland 80 40 
Great Britain 80 40 
Ireland 79 39 
Netherlands 80 40 
New Zeeland 80 40 
Norway 81 41 
Sweden 81 41 
United States 78 38 
Source: The World Bank (2014) 
 
2. GDP per capita 
Table 6: GDP per capita 
Country PPP adjusted GDP per capita 
Australia 39165 
Canada 40022 
Finland 38080 
Great Britain 36588 
Ireland 42133 
Netherlands 42929 
New Zeeland 29083 
Norway 61332 
Sweden 39613 
United States 48336 
In US dollar, Source: The World Bank (2014) 
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3. Value of statistical life 
Table 7: VSL 
Country VSL  
Australia 1193378 
Canada 1408630 
Finland 1273372 
Great Britain 2107000 
Ireland 1170695 
Netherlands 1741000 
New Zeeland 1704131 
Norway 2707000 
Sweden 1954000 
United States 3189000 
In Euros (2002 PPP adjusted rates), Source: SafetyNet (2009) 
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4. EuroVaQ 
Table 8: EuroVaQ health states 
QALY 
change 
Scenario Notation - Green 
health state 
Notation - Yellow 
health state2 
0.05 100 % time Gm Yq 
0.05 1 year risk Gj Yh 
0.10 100 % time Gn Yr 
0.10 1 year risk Gd Yi 
0.10 10 year risk Gf  
Varies 1 year with certainty Ga Yb 
Varies 1 year with certainty - annual 
payment for 4 years 
 Ye 
Source: Figure 3.13a EuroVaQ (2010) 
 
Table 9: WTP and response rates from EuroVaQ 
 Great Britain Netherlands Norway Sweden 
WTP 23526 25296 41456 30131 
Response rate (SSI) 5.6% 15.5 % 7.7 % 12 % 
Response rate (Partner) 6 % 15 % 10 % 8 % 
Invites 87312 61773 29618 45752 
Starters 4932 9544 2288 5492 
Source: EuroVaQ (2010) 
Means for the two different health states, green and yellow, and the WTP for every scenario is 
available in table 10 below.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 10: WTP for a QALY 
All values in US Dollar, Number of respondents in parenthesis, Source: EuroVaQ (2010) 
 
 
 
 
 
Notation - Green 
health state 
Notation - Yellow 
health state 
Great 
Britain 
 Netherlands  Norway  Sweden  
  Green 
Mean WTP 
Yellow 
Mean WTP 
Green  Mean 
WTP 
Yellow 
Mean WTP 
Green 
Mean WTP 
Yellow 
Mean WTP 
Green 
Mean WTP 
Yellow 
Mean WTP 
Ga Yb 12421 
(894) 
22762 
(914) 
12862 
(1038) 
22951 
(1058) 
45518 
(846) 
43438 
(831) 
23261 
(1104) 
33555 
(1099) 
Gj Yh 23267 
(459) 
23285 
(394) 
24892 
(504) 
23133 
(439) 
37427 
(365) 
29474 
(288) 
35200 
(500) 
27696 
(428) 
Gd Yi 21182 
(882) 
14848 
(646) 
22211 
(1017) 
16819 
(759) 
33685 
(760) 
21602 
(523) 
34824 
(1056) 
16908 
(767) 
Gm Yq 29308 
(953) 
20525 
(960) 
27418 
(1119) 
27345 
(1124) 
41298 
(807) 
41003 
(801) 
28805 
(1107) 
33142 
(1100) 
Gn Yr 15897 
(954) 
13228 
(942) 
18623 
(1111) 
15738 
(1089) 
26399 
(818) 
24757 
(794) 
19287 
(1122) 
18292 
(1095) 
Gf Ye 25245 
(421) 
60342 
(523) 
22911 
(475) 
68643 
(575) 
39136 
(413) 
113730 
(418) 
27471 
(542) 
63128 
(569) 
Average Mean 
WTP 
- 23526 - 25296 - 41456 - 30131 - 
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5. QALY Thresholds 
Table 11: QALY Thresholds 
Country QALY Threshold 
value (US Dollar) 
Source(s): Comments 
Australia 51384 George et al (2001) The numbers are the top value where the Australian government would approve for policy according to 
an investigation of the Australian government. The source and the values old but the numbers are 
confirmed by the KCE (2008) who report a value close to the number used in the thesis 
Canada 64809 KCE (2008) The threshold value is from a report by the Belgian KCE which is a federal research centre in Belgium, 
KCE refers the numbers as implicit, in other word not official. 
Finland 76284 Hallinen et al (2011) In Finland there is no official threshold, in many cases twice the GNP per capita has worked as a 
guideline. That number is around 70 000 Euros. The figure of 50 000 has also been mentioned but again I 
chose to use the higher threshold since it could be as high as 70 000. 
Great Britain 33706 NICE (2009) Official numbers from NICE (National Institute for Health and Care Excellence). The numbers are 
frequently mentioned in the literature and are treated with respect, the values ranges from 20 000- 30 000 
in domestic currency. 
Ireland 47292 HIQA (2014) No official number but historical references. HIQA (Health Information and Quality Authority) in Ireland 
has that the interval between 20 000-45 000 Euros is usually used. Again, the upper bound has been 
selected as a reference for Ireland 
Netherlands 94975 KCE (2008) The threshold value is from a report by the Belgian KCE which is a federal research centre in Belgium, 
KCE refers the numbers as implicit, in other word no official. 
New Zeeland 13416 KCE (2008) The threshold value is from a report by the Belgian KCE which is a federal research centre in Belgium, 
KCE refers the numbers as implicit, in other word no official. 
Norway 57129 Cost-Benefit analysis, 
(2012) 
The threshold value is from a report by the Norwegian Ministry of Finance. The report states that 
Norwegian health sector usually uses a value of NOK 500 000. However the same report also suggests 
the use of VSL for all sectors. Again the values are not official but the threshold stated seems to be used 
in economic evaluation in Norway 
Sweden 68389 Influensan A(H1N1), 
(2009) 
The threshold value is from a CBA regarding the swine flu in 2009. The authors refer to unofficial 
interviews with TLV. The CBA was conducted by Swedish authorities and they refer to TLV, so even if 
the numbers are not official it seems that the threshold is actually used by policymakers 
United States 100000 Shiroiwa et al (2010) The threshold for United Sates is in a major interval ranging between 50 000-100 000, the numbers are 
mentioned in the literature and seems to be accepted even though they are not official. I have chosen 
100 000 as it is the upper bound, however, other argues for the use of 50 000 (see Weinstein 2008) 
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